Suppr超能文献

冠状动脉内长期输注尿激酶治疗冠状动脉慢性完全闭塞病变的前瞻性随机试验。

Prospective, randomized trial of prolonged intracoronary urokinase infusion for chronic total occlusions in native coronary arteries.

作者信息

Zidar F J, Kaplan B M, O'Neill W W, Jones D E, Schreiber T L, Safian R D, Ajluni S C, Sobolski J, Timmis G C, Grines C L

机构信息

Department of Cardiology, Department of Medicine, William Beaumont Hospital, Royal Oak, Michigan 48073, USA.

出版信息

J Am Coll Cardiol. 1996 May;27(6):1406-12. doi: 10.1016/0735-1097(96)00010-1.

Abstract

OBJECTIVES

The purpose of this study was to determine the safety and efficacy of three dosing regimens of intracoronary urokinase for facilitated angioplasty of chronic total native coronary artery occlusions.

BACKGROUND

Percutaneous transluminal coronary angioplasty of chronically occluded (>3 months) native coronary arteries is associated with low initial success secondary to an inability to pass the guide wire beyond the occlusion.

METHODS

Patients were enrolled if a chronic total occlusion >3 months old could not be crossed with standard angioplasty equipment. Of the 101 patients enrolled, 41 had successful guide wire passage and were excluded from urokinase treatment. The remaining 60 patients were randomized to receive one of three intracoronary dosing regimens of urokinase over 8 h (group A = 0.8 million U; group B = 1.6 million U; group C = 3.2 million U), and angioplasty was again attempted after completion of the urokinase infusion in 58 patients.

RESULTS

Coronary angioplasty was successful in 32 patients (53%) (group A 52%, group B 50%, group C 59%, p = 0.86). This study had a 90% power to detect at least a 50% difference between dosing groups at alpha 0.05. Bleeding complications requiring blood transfusion did not differ significantly among the dosing groups (A 0%, B 15%, C 6%, p = 0.14), although major bleeding episodes were less common in group A (p < 0.05). There were no major procedural or in-hospital complications. Angiographic follow-up in 69% of the patients with successful angioplasty revealed target vessel patency in 91% but an angiographic restenosis rate of 59%.

CONCLUSIONS

A prolonged supraselective intracoronary infusion of urokinase can be safely administered and may facilitate angioplasty of chronic total occlusions. Lower doses of urokinase are equally effective and result in fewer bleeding complications than do higher dosage regimens. Vessel patency is frequently maintained, but restenosis remains a problem.

摘要

目的

本研究旨在确定冠状动脉内注射三种剂量尿激酶方案用于促进慢性完全性自身冠状动脉闭塞病变血管成形术的安全性和有效性。

背景

对慢性闭塞(>3个月)的自身冠状动脉进行经皮腔内冠状动脉成形术,由于无法将导丝通过闭塞段,初始成功率较低。

方法

入选标准为年龄>3个月的慢性完全闭塞病变不能被标准血管成形术器械通过的患者。在入选的101例患者中,41例成功通过导丝,被排除在尿激酶治疗之外。其余60例患者随机分为三组,在8小时内接受三种冠状动脉内尿激酶给药方案之一(A组=80万单位;B组=160万单位;C组=320万单位),58例患者在尿激酶输注完成后再次尝试血管成形术。

结果

32例患者(53%)血管成形术成功(A组52%,B组50%,C组59%,p=0.86)。本研究在α=0.05水平上有90%的把握度检测到给药组之间至少50%的差异。需要输血的出血并发症在给药组之间无显著差异(A组0%,B组15%,C组6%,p=0.14),尽管A组严重出血事件较少(p<0.05)。无严重手术或住院并发症。69%血管成形术成功的患者进行血管造影随访显示,靶血管通畅率为91%,但血管造影再狭窄率为59%。

结论

长时间超选择性冠状动脉内输注尿激酶可安全给药,并可能促进慢性完全闭塞病变的血管成形术。较低剂量的尿激酶同样有效,且与较高剂量方案相比出血并发症更少。血管通常能保持通畅,但再狭窄仍是一个问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验